Dataset Information

B cells and tertiary lymphoid structures promote immunotherapy response.

ABSTRACT: Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers^1-10 and strategies to augment clinical response have largely focused on the T cell compartment. However, other immune subsets may also contribute to anti-tumour immunity^11-15, although these have been less well-studied in ICB treatment¹⁶. A previously conducted neoadjuvant ICB trial in patients with melanoma showed via targeted expression profiling¹⁷ that B cell signatures were enriched in the tumours of patients who respond to treatment versus non-responding patients. To build on this, here we performed bulk RNA sequencing and found that B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders. Our findings were corroborated using a computational method (MCP-counter¹⁸) to estimate the immune and stromal composition in this and two other ICB-treated cohorts (patients with melanoma and renal cell carcinoma). Histological evaluation highlighted the localization of B cells within tertiary lymphoid structures. We assessed the potential functional contributions of B cells via bulk and single-cell RNA sequencing, which demonstrate clonal expansion and unique functional states of B cells in responders. Mass cytometry showed that switched memory B cells were enriched in the tumours of responders. Together, these data provide insights into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.

SUBMITTER: Helmink BA

PROVIDER: S-EPMC8762581 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

B cells and tertiary lymphoid structures promote immunotherapy response.

Helmink Beth A BA Reddy Sangeetha M SM Gao Jianjun J Zhang Shaojun S Basar Rafet R Thakur Rohit R Yizhak Keren K Sade-Feldman Moshe M Blando Jorge J Han Guangchun G Gopalakrishnan Vancheswaran V Xi Yuanxin Y Zhao Hao H Amaria Rodabe N RN Tawbi Hussein A HA Cogdill Alex P AP Liu Wenbin W LeBleu Valerie S VS Kugeratski Fernanda G FG Patel Sapna S Davies Michael A MA Hwu Patrick P Lee Jeffrey E JE Gershenwald Jeffrey E JE Lucci Anthony A Arora Reetakshi R Woodman Scott S Keung Emily Z EZ Gaudreau Pierre-Olivier PO Reuben Alexandre A Spencer Christine N CN Burton Elizabeth M EM Haydu Lauren E LE Lazar Alexander J AJ Zapassodi Roberta R Hudgens Courtney W CW Ledesma Deborah A DA Ong SuFey S Bailey Michael M Warren Sarah S Rao Disha D Krijgsman Oscar O Rozeman Elisa A EA Peeper Daniel D Blank Christian U CU Schumacher Ton N TN Butterfield Lisa H LH Zelazowska Monika A MA McBride Kevin M KM Kalluri Raghu R Allison James J Petitprez Florent F Fridman Wolf Herman WH Sautès-Fridman Catherine C Hacohen Nir N Rezvani Katayoun K Sharma Padmanee P Tetzlaff Michael T MT Wang Linghua L Wargo Jennifer A JA

Nature 20200115 7791

Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers1-10 and strategies to augment clinical response have largely focused on the T cell compartment. However, other immune subsets may also contribute to anti-tumour immunity11-15, although these have been less well-studied in ICB treatment16. A previously conducted neoadjuvant ICB trial in patients with melanoma showed via targeted expression profiling< ...[more]

PMID: 31942075

Similar Datasets

Project description:Immunotherapy provides an alternative approach for cancer treatment. However, in-depth analyses of the effects of immunotherapy on the tumor microenvironment (TME) have not been conducted in non-melanoma tumors. Here we describe changes in the pancreatic ductal adenocarcinoma (PDAC) TME following immunotherapy treatment, and show for the first time that vaccine-based immunotherapy directly alters the TME, inducing neogenesis of tertiary lymphoid structures that convert immunologically quiescent tumors into immunologically active tumors. Alterations in five pathways important for immune modulation and lymphoid structure development (TH17/Treg, NFkB, Ubiquitin-proteasome, Chemokines/chemokine receptors, and Integrins/adhesion molecules) in vaccine-induced intratumoral lymphoid aggregates were associated with improved post-vaccination responses. Additional studies in other cancers and patients treated with other forms of immunotherapy are warranted to further develop signatures defined in intratumoral lymphoid structures into biomarkers that predict effective anti-tumor immune responses. These signatures may also expose therapeutic targets for promoting more robust antitumor immune responses in the TME. Between July 2008 and September 2012, 59 patients were enrolled into an ongoing study of an irradiated, allogeneic GM-CSF-secreting pancreatic tumor vaccine (GVAX) administered intradermally either alone or in combination with immune modulatory doses of cyclophophamide (Cy) as neoadjuvant and adjuvant treatment for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Patients were randomized 1:1:1 to 3 treatment arms. In Arm A, patients received GVAX alone; in Arm B, patients received GVAX plus a single intravenous dose of Cy at 200 mg/m2 1 day prior to each vaccination; in Arm C, patients received GVAX plus oral Cy at 100 mg once daily for 1 week on and 1 week off. Up to 6 GVAX treatments were administered and all of the patients remained in their initial treatment arms throughout the duration of the study. All 59 of the patients received the 1st GVAX treatment 2 weeks +/-4 days prior to surgery. Formalin-fixed paraffin-embedded (FFPE) tissue blocks of surgically resected PDAC were obtained from the pathology archive. FFPE tissue blocks from each subject were stained by H&E immediately before the vaccine therapy-induced lymphoid aggregates were microdissected . To better understand the functional status of these vaccine therapy induced lymphoid aggregate structures, gene microarray analysis on RNA isolated from microdissected lymphoid aggregates was performed. Gene expression was compared among samples grouped according to patient overall survival, post-vaccination induction of enhanced mesothelin-specific T cell responses in peripheral blood lymphocytes (PBL), and the intratumoral CD8+ T effector to FoxP3+ Treg ratio. Post-vaccination induction of enhanced mesothelin-specific T cell responses has been reported to correlate with longer survival in patients treated with Panc GVAX.

Dataset Information

B cells and tertiary lymphoid structures promote immunotherapy response.

Publications

B cells and tertiary lymphoid structures promote immunotherapy response.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets